Integra LifeSciences (IART) Tops Q2 EPS by 1c ; Offers Guidance

Integra LifeSciences (NASDAQ: IART) reported Q2 EPS of $0.45, $0.01 better than the analyst estimate of $0.44. Revenue for the quarter came in at $415.6 million versus the consensus estimate of $395.04 million.

GUIDANCE:

Integra LifeSciences sees Q3 2025 EPS of $0.40-$0.45, versus the consensus of $0.58. Integra LifeSciences sees Q3 2025 revenue of $410-420 million, versus the consensus of $418.8 million.

Integra LifeSciences sees FY2025 EPS of $2.19-$2.29, versus the consensus of $2.24. Integra LifeSciences sees FY2025 revenue of $1.65-1.68 billion, versus the consensus of $1.66 billion.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Armata gets $2.5M more in DoD funding for bacteriophage drug
• e-STORAGE and Axpo to deploy 8 MW battery system in southern Italy